Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Capital Expenditures (2017 - 2025)

Historic Capital Expenditures for Denali Therapeutics (DNLI) over the last 9 years, with Q3 2025 value amounting to -$1.4 million.

  • Denali Therapeutics' Capital Expenditures fell 13547.89% to -$1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.1 million, marking a year-over-year increase of 11.49%. This contributed to the annual value of $15.9 million for FY2024, which is 2297.7% up from last year.
  • According to the latest figures from Q3 2025, Denali Therapeutics' Capital Expenditures is -$1.4 million, which was down 13547.89% from $4.3 million recorded in Q2 2025.
  • In the past 5 years, Denali Therapeutics' Capital Expenditures registered a high of $6.1 million during Q1 2023, and its lowest value of -$1.4 million during Q3 2025.
  • Moreover, its 5-year median value for Capital Expenditures was $3.1 million (2021), whereas its average is $3.3 million.
  • As far as peak fluctuations go, Denali Therapeutics' Capital Expenditures surged by 27474.09% in 2022, and later plummeted by 13547.89% in 2025.
  • Denali Therapeutics' Capital Expenditures (Quarter) stood at $3.1 million in 2021, then soared by 58.83% to $4.8 million in 2022, then plummeted by 53.91% to $2.2 million in 2023, then soared by 127.83% to $5.1 million in 2024, then crashed by 127.06% to -$1.4 million in 2025.
  • Its Capital Expenditures stands at -$1.4 million for Q3 2025, versus $4.3 million for Q2 2025 and $5.1 million for Q1 2025.